Shufang Gu

968 citations
13 papers · 807 indexed · h-index 12
Topics
NF-κB Signaling Pathways (5 papers)Adipokines, Inflammation, and Metabolic Diseases (2 papers)Blood Coagulation and Thrombosis Mechanisms (2 papers)

In The Last Decade

Shufang Gu

13 papers receiving 801 citations

Peers

Shufang Gu
Comparison fields: 5 of 70
  • Immunology 281
  • Cancer Research 272
  • Molecular Biology 247
  • Epidemiology 166
  • Physiology 133
Replace Kevin Croce with:
Kevin Croce United States
Rajinikanth Gogiraju Germany
Gersina Rega‐Kaun Austria
Chiao Guo United States
Junichiro Tohyama United States
Begüm Kocatürk United States
Hilal Oğuz Türkiye
Chongxiu Sun United States
Andrea E. Bochem Netherlands
Xia V. Yang United States
Shufang Gu relative to Kevin Croce United States Kevin Croce's profile →
Citations per field
00.5×1.5×2.4×
Kevin Croce · 1×
Citations per year

Countries citing papers authored by Shufang Gu

Since Specialization
Citations

This map shows the geographic impact of Shufang Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shufang Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shufang Gu more than expected).

Fields of papers citing papers by Shufang Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shufang Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shufang Gu. The network helps show where Shufang Gu may publish in the future.

Co-authorship network of co-authors of Shufang Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Shufang Gu. A scholar is included among the top collaborators of Shufang Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shufang Gu. Shufang Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
#WorkIndexed citations
1 19
2 1
3 35
4 55
5 44
6 120
7 64
8 71
9 140
10 53
11 115
12 24
13 66

About Shufang Gu

Shufang Gu is a scholar working on Cancer Research, Immunology and Allergy and Endocrine and Autonomic Systems, having authored 13 papers that have together received 807 indexed citations. Recurring topics across this work include NF-κB Signaling Pathways (5 papers), Adipokines, Inflammation, and Metabolic Diseases (2 papers) and Blood Coagulation and Thrombosis Mechanisms (2 papers). The work is most often cited by research in Cancer Research (272 citations), Immunology (281 citations) and Hematology (114 citations). Shufang Gu has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Peter C. Lucas, Linda M. McAllister‐Lucas, Yuechun Shen, Peter F. Bodary, Daniel T. Eitzman, Xiaohong Jin, Alyssa H. Hasty, Jürgen Ruland, Ingrid J. Apel and Phillip C. Delekta. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026